Dungloe to host Randox Health Grand National Celebration Event
In celebration of this year’s Randox Health Grand National, the sponsors of the world’s greatest race are hosting a Family Fun Day in Dungloe, Donegal on Saturday 14th April.
Held at Randox Teoranta, the world-leading life sciences, engineering and manufacturing facility, the event will mark how far the company has come as it takes to the world stage for the Randox Health Grand National, and recognise the support the company has received from the local community since its establishment in Dungloe in 2008.
Randox Managing Director, Dr Peter FitzGerald, commented;
“Our aim to offer world-leading science, engineering, software and manufacturing careers in west Donegal, so that people working in these fields no longer have to move away from home to find work, has been incredibly well-received. We’re therefore delighted that we will be able to join together in Dungloe on Randox Health Grand National Day to celebrate how far we have come.
“With performances from Laura Aisling Academy of Irish Dance and Fitness, and traditional music played by the Rosses Community School, it is sure to be a wonderful event celebrating all aspects of our Irish heritage – including of course traditional music and dance but also the thriving equestrian scene and the many Irish horses who will be running in the Randox Health Grand National!”
Taking place between 1pm and 6pm on Grand National Day, the event is free for all the family, with plenty of entertainment, including a bouncy castle, live music and dance, and a rodeo bull, as well as food, drink, craft stalls and a large screen for the public to watch the Randox Health Grand National at Aintree in Liverpool.
Guests to the Family Fun Day will be joined by radio personality Seán Bán Breathnach, who will be presenting RTÉ Raidió na Gaeltachta’s sports programme Spórt an tSathairn live from the event.
Seán Bán Breathnach, RTÉ Raidió na Gaeltachta, commented;
“I’m really looking forward to the live programme. It will be a great day out for the community thanks to Randox Health, and there’s sure to be a brilliant atmosphere so I’d encourage people to come along. I can still remember listening to my first ever Grand National, back in 1958, on our new family wireless radio. That year, for the first time in many years, it was won by an Irish horse Mr. What, and who knows, maybe we’ll be lucky again this year!”
Following the reveal of the new Randox Health Grand National trophy on Thursday 12th April, the event will also host an art competition, for which school students in the area have been asked to submit their own trophy designs for the world’s greatest race. Winners will be announced on the day.
For more information or to arrange interviews, please contact Randox PR on 028 9442 2413 or email email@example.com
Mycotoxin contamination is a real and constant threat for feed and animal compound producers globally. Recently the University of Guelph, Guelph, Ontairo stated that the different geographical locations of cattle mean between 10 and 20 mycotoxins can be present at once. This is a result of extreme weather patterns across the US with excess moisture and drought in different areas causing an increase in the frequency of mycotoxins, creating challenges in protecting livestock from ingesting contaminated feed.
The most common mycotoxins found are Aflatoxin, Fusarium, Deoxynivalenol and Zearalenone. Aflatoxin is produced by Aspergillus flavus, a tropical fungus that thrives in high humidity and affects an animal’s liver, causing cancer in more extreme cases. Fusarium can develop in most temperate climates across the U.S and Canada. Fusarium poses a higher threat than other toxins as there are hundreds of different chemical structures to analyse to enable identification of the Fusarium.
Difficulties also arise in finding an analytical method sensitive enough to detect mycotoxins at low levels of contamination as small amounts can still lead to fatal results in horses, dogs and cats.
To prevent mycotoxin infection in feed, processors can implement a routine screening procedure with the help of Randox Food Diagnostics. Randox Food offer a multiplex screening system for the simultaneous detection of up to 10 of the world’s most prevalent mycotoxins including: Paxilline, Fumonisins (part of the Fusarium group), Ochratoxin A, Aflatoxin G1/G2, Aflatoxin B1/B2, Ergot Alkaloids, Diacetoxyscirpenol, Deoxynivalenol, T2 Toxin and Zearalenone. All compounds are screened at low limits of detection using Biochip Array Technology.
Biochip Array Technology is a patented technology created by Randox to facilitate the detection of contaminants and drug residues with over 20 evaluated matrices in feed (see full list below).
|Animal Feed (Complete)||Millet||Sunflower|
|Cotton Seed||Rye||Feed Pea|
|Distillers Grain||Silage||Vetches (Vica)|
A dramatic increase in global consumption of antibiotics has led public health experts to call for innovative new ways to rein in excessive use of the drugs, following a study by the Centre for Disease Dynamics, Economics and Policy, in Washington DC.
The study found a 65% rise in worldwide consumption of antibiotics from 2000 to 2015, despite efforts to encourage more prudent use of the drugs. The unrestrained use of antibiotics is the main cause of the increasing appearance of drug-resistant infections, which now kill more than half a million people worldwide. A report in 2014 predicted that the spread of drug resistance could claim millions of lives per year by 2050.
Eili Klein, an author of the study, which was published in Proceedings of the National Academy of Science, criticised the global response to the global antibiotic resistance crisis as “slow and inadequate” and called for a “radical thinking” of antibiotic consumption.
At Randox, our pioneering R&D teams have developed a revolutionary swab test for respiratory infections which will help to reduce the unnecessary prescription of antibiotics. Earlier this year, Public Health England reported that 59% of people who visited their GP with a sore throat were prescribed antibiotics, in spite of only 13% actually needing them.
The new Randox swab test indicates the cause of the infection and whether a patient needs antibiotics or not, by rapidly detecting and identifying the cause of 21 respiratory infections in just 5 hours
The test assists the clinician in prescribing the appropriate antibiotic.
John Lamont, Lead Scientist at Randox Laboratories, said;
“Current diagnostic testing for respiratory infections takes at least 36 hours to confirm the nature of an infection, and they cannot name and categorise infections as bacterial or viral in the way our new respiratory test can.”
This test, if widely adopted, could allow medical practitioners to make the correct treatment choice on the same day as examination and before patients have already begun a precautionary course of inefficient antibiotics. It would also have additional efficiency savings for the NHS, by eliminating the need for lengthy microbiology lab tests and unnecessarily prescribing drugs which are not needed.
This new rapid and accurate test will give clinicians confidence in their diagnosis of respiratory infections and will allow for quicker treatment if necessary, which benefits patient outcomes. By reducing the prescription of unnecessary antibiotics, we can limit their use only for when they are truly needed.
The test is also available as a Randox Health Cough, Cold & Flu offering, and can be carried out by booking an appointment with Randox Health at our clinics in Crumlin, Holywood or London, or by arranging the mobile clinic to visit you at your home or place of work.
Book an appointment with one of our clinics, or arrange the mobile clinic, by phoning 0800 2545 130 or by clicking here.
For further information about the Randox Respiratory Infection Array please contact the Randox PR team by email: firstname.lastname@example.org or phone 028 9442 2413
Have you heard about our latest offering? Randox Clinical Laboratory Services now offers a multiplex Sexually Transmitted Infection Array testing service allowing your clinic, laboratory or GP practice to outsource sample STI testing.
Our STI array is the broadest multiplex test on the market, simultaneously detecting 10 bacterial, viral and protozoan infections. It consists of the following most common STIs, Chlamydia, Gonorrhoea, Syphilis, Herpes Simplex I, Herpes Simplex II, Trichomonas Vaginalis, Mycoplasma Hominis, Mycoplasma Genitalium, Ureaplasma Urealyticum and Chancroid. This simultaneous detection is made possible by our patented and innovative Biochip Array Technology which utilises multiplex testing methodology in a rapid and accurate format.
There are many benefits to outsourcing your STI samples with RCLS, which include:
- ISO17025 Accredited Laboratories
- Excellent precision, specificity, sensitivity and accuracy for STI diagnosis
- Reduced risk of false reporting and a reduced number of unnecessary confirmatory tests
- Smaller sample volumes are required, enabling faster throughput and rapid patient diagnosis
The type of sample which should be sent to our RCLS lab is determined by the visibility of the patient’s symptoms.
Non-visible symptoms – urine sample required.
Visible symptoms – swab sample required.
The process for sending STI samples to Randox Clinical Laboratory Services is simple and easy to follow. Georgia Roberts, our RCLS representative will guide you through the process from your initial enquiry to pricing and shipment of samples.
All RCLS laboratories utilise our world class clinical chemistry analysers, the RX Series, along with our multiplex immunoassay analysers, the Evidence Series. We also perform sample testing on numerous third party analysers situated in our laboratories dependent upon the testing which is required by the customer.
RCLS incorporates multiple laboratories across the United Kingdom including our state-of-the-art facility in Antrim, as well as further laboratories in Belfast, Liverpool and London. RCLS is ever expanding with plans to open another facility in Los Angeles.
Overall, by utilising Randox Clinical Laboratory Services you can save your laboratory time and money. Due to our multiplex panels we offer a cost effective, labour saving and time reducing solutions for your STI testing. Providing your laboratory with the best solution to outsource your samples.
If you would like to find out more information about RCLS and what it has to offer contact email@example.com
Systemic Lupus Erythematosus (SLE) is an autoimmune disorder associated with a deficiency in complement C4. Complement C4 is one of nine components of the complement system which is an integral part of the immune system that enhances (complements) the ability of antibodies and phagocytic cells to clear microbes and damaged cells from the host, promote inflammation, and attack the cell membrane of pathogens.
Complement C4 is a vital component of two immunology pathways: Classical pathway and Mannrose Binding Lectin (MBL) pathway.
The classical pathway is triggered by antibody-antigen complexes which induces a conformational change in the C1 complex. The activated C1 complex cleaves the C4 component, resulting in a reactive C4b which covalently binds to proteins or polysaccharides at the surface in close proximity of the C1 component. The bound C4b complexes binds to the C2 component rendering C2 for proteolysis by C1.
The MBL pathway is activated through the binding of MBL to mannose residues on the pathogen surface. This in turn activates the MBL-associated serine proteases, MASP-1 and MASP-2, which activates the C4 and C2 components, to form the C3 convertase, C4b2a. The C4b2a complex splits C3 into two fragments which causes the release of vasoactive mediators such as histamine.
Complement C4 deficiency is commonly associated with systemic lupus erythematosus (SLE).
According to lupus.org, 16,000 new cases of lupus are reported each year. Approximately 1 in 250 people may end up developing SLE at some point with 90% of SLE patients being female aged between 15-44 years. The causes of SLE are unknown, but are believed to be linked to environmental, genetic, and hormonal factors. 1.5 million Americans are living with diagnosed lupus.
There are four forms of lupus:
- Systemic – accounts for approximately 70% of all lupus cases. In half of these cases, a major organ or tissue in the body, such as the heart, lungs, kidneys, or brain will be affected.
- Cutaneous lupus – accounts for approximately 10% of all lupus cases and only affects the skin.
- Drug-induced lupus accounts for approximately 10% of all lupus cases and is caused by high doses of certain medications.
- Neonatal lupus is a rare condition in which the mother’s antibodies affect the fetus. At birth, the baby may have a skin rash, liver problems, or low blood cell counts, but these symptoms typically disappear completely after six months with no lasting effects.
The Randox Complement C4 assay
The Randox Complement C4 assay is used for the quantitative in vitro determination of complement C4 concentration in serum. The Randox Complement C4 assay can be used as a biomarker in the diagnosis and monitoring of SLE. It is the cell-bound levels of processed complement activation products, especially E-C4d (erythrocyte-bound C4) that makes the complement C4 assay a biomarker for SLE.
Key Features of the Randox Complement C4 assay
Liquid ready-to-use reagents – The Randox reagent comes in a convenient liquid format requiring minimal preparation thus reducing the risk of errors.
Exceptional correlation with standard methods – The Randox methodology was compared against other commercially available methods and the Randox Complement C4 assay showed a correlation coefficient of r=0.98.
Wide measuring range – The healthy range for Complement C4 is 7 -49 mg/dl. The Randox Complement C4 assay can comfortably detect levels outside of the healthy range measuring between 2.90 – 152 mg/dl.
Almost a year to the day of the tragic death of the “King of Heswall” Tim Cogley, his father will be joined by some of the UK’s best-known sports stars at an event in Liverpool to raise awareness of how lives can be saved through improving access to earlier routine health screening.
On April 9th 2017 Tim, who was only 34-years old, suffered a fatal heart attack due to a genetic condition which could have been managed had it been diagnosed earlier. It spurred his father, Frank Cogley, to set up a charity to raise awareness of the importance of health checks for young people.
He’ll be joined at the free Randox Health Week event in Exchange Station on 11th April by legendary jockey Sir AP McCoy, champion boxer Paul Smith and Olympic sailor Matt McGovern. The public will be invited to join the discussions as well.
Frank said: “It’s been recently reported that at least 12 under-35s die from undiagnosed heart conditions every week in the UK. The current lack of routine screening of 18-40-year olds leaves a gaping chasm in our healthcare provision. With our highly motivated partners, through events like this, we hope to redress this through lifestyle changes and preventative medical programmes. The ‘Tim Cogley Cardiac Screening Foundation’ is committed to delivering positive, action-focused and life-changing programmes. I can’t imagine a legacy more in tune with the generous, kind and supportive person that was Tim!”
This is the second year that Randox Health Week has been held in the city. The areas of mental health and active cities will be explored on days one and two – the 9th and 10th respectively. On each of the mornings, local athletes Franny Norton and Derry Mathews will be putting pupils to the test with a range of sporting activities at LJMU’s Byrom Street campus.
By working with the city’s leading universities – Liverpool John Moores and Liverpool Hope – cutting-edge innovations in healthcare and emerging trends are being shared with a global audience. One such ground-breaking development is a test for prediabetes which is key to tackling the worldwide threat of preventable cases of Type-2 diabetes. It’s something that legendary jockey Sir Anthony McCoy, also taking part in Wednesday’s talk, has first-hand experience of:
“When I got my first test results back that said I had prediabetes, it floored me. I had never imagined that I, someone who had been a professional athlete all of my life, could develop it. It just goes to show that we’re all vulnerable. I only wish it had been around when it could have helped my mum who lived with Type-2 diabetes for many years. As daunting as it was getting the diagnosis, it’s been empowering to very simply make lifestyle changes to reverse it. This needs to be accessible to everyone – it needs to be on the national diabetes screening programme.”
Dr Peter FitzGerald, Managing Director of Randox Health, commented: “The themes we’re focusing on this week are some of the most important global concerns facing us today – mental health, physical activity and showing people the benefits to being proactive about their health, rather than facing the consequences of preventable sickness. You need look no further than Frank Cogley who is working tirelessly to turn his son’s tragic death into a force for good to see how important this is. With the support from AP McCoy and Paul Smith, we hope this event will inspire many people in the city and beyond.”
Tickets are free and can be reserved at www.eventbrite.co.uk/e/randox-health-week-2018-tickets-43648350391
For further information about Randox Health Week, please contact the Randox PR team by email: firstname.lastname@example.org or by phone: 028 9442 2413
Biochip Array Technology is the fundamental component which drives the Randox Evidence Series immunoanalysers. The simultaneous detection of multiple analytes from a single sample allows for a complete patient profile, providing exceptional time, resource and cost savings.
The Evidence Series analysers all carry the Biochip in different applications. In order to gain a better understanding of how it is utilised, the illustrations below demonstrate how adaptable and flexible the technology is across the Evidence Series.
- One strip contains 10 biochips
- Analyser can hold 20 strips
- Can produce a throughput of up to 2640 tests per hour
- Each cassette contains 10 carriers
- Each carrier has 9 wells
- Analyser can hold 4 cassettes at once
- Can produce a throughput of up to 3960 tests per hour
- Analyser holds 1 cartridge
- 1 cartridge contains 9 wells
- Thermoshaker capable of carrying 6 cartridges
- Can produce a throughput of up to 2376 tests per hour
- Analyser holds 1 cartridge
- Cartridge comes pre-loaded with reagents and QC
- Can produce a throughput of up to 132 tests per hour
About the Randox Evidence Series
The Evidence Series is set to revolutionise diagnostic testing forever. Offering unrivalled capabilities across all analysers, we truly believe that the Evidence Series range of immunoassay analysers can meet your diagnostic testing capabilities.
Neighbourhoods across Spain recently came together to form the National Network of Cities and Neighbourhoods affected by Narcopisos, which are abandoned buildings used as drug flats. The Guardian reported how the organisation aims to raise awareness of Spain’s drug problem and shut down the empty properties being used as distribution points to buy, smoke and inject heroin.
Neighbours living close to narcopisos have described the scene as filthy, loud and dangerous. Blood, faeces and syringes have been found on the stairs and doorways to the buildings accompanied with people passing out or fighting. With cheap heroin of a poor quality, the largest narcopiso in Carrer d’en Roig was shut down after receiving up to 150 clients an hour. Barcelona’s city council cleaned up areas and secured properties in Raval as part of a €500,000 project. However, drug dealers are reportedly moving quicker than the courts and police.
When it comes to heroin, dealers do not discriminate and neither does the product. Business executives, pregnant women, teenagers and people with disabilities have all been victim to narcopisos in Spain. In areas such as La Linea de la Concepción, unemployment is at 80% and drug dealing is seen as an opportunity for the youth to make money. In 2017, director the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Alexis Goosdeel reported, “Opioids and often heroin, are present in the majority of cases, often in combination with alcohol or benzodiazepine.”
Utilising our patented Biochip Array Technology, our DoA ULTRA panel offers the most comprehensive drugs of abuse screen across multiple forensic matrices. Detecting up to 20 targets drugs including heroin and other opioids, it has the largest cross-reactivity profile of over 240 analytes. Our excellent assay precision and performance eliminates false reporting, offering CVs of typically <10%. Randox Toxicology produce an accurate drug profile to ensure confidence in results.
Randox Laboratories are pleased to announce that Managing Director Dr Peter FitzGerald has been named as the Irish Times’ Business Person of the Month for February 2018.
The award follows an announcement from Randox that the company will be investing £50m into three new Centres of Excellence in Northern Ireland, which will deliver cutting-edge technologies to diagnose conditions like cancer, heart conditions and infectious diseases.
At the time of the announcement, Dr FitzGerald commented;
“Enabling earlier and more accurate diagnosis, to identify those at the earliest stages of illness, ideally before the onset of any symptoms, is a game-changer. Through early intervention we can restrict the development of chronic conditions and improve people’s lives. Our view of the future is one where people are empowered through earlier diagnosis to stay healthier for longer, and where healthcare systems are freed to deliver quality services to patients. Our announcement today demonstrates our continuing commitment in this field.”
Scientists from the Antrim-headquartered group will work collaboratively with researchers and scientists from both Queen’s University and Ulster University in the new centres, which were launched at the new Randox Science Park by Sir John Bell.
In addition to the Randox Science Park, Randox has manufacturing, and research and development operations in Antrim, Donegal, India and the United States, and employs more than 1400 people across the globe.
Having been focused in the field of clinical diagnostics for over 36 years, Randox has a successful track record of developing new and innovative tests – examples include assessing those at risk of Alzheimer’s disease and genetic cardiac conditions, to promote and enable preventive treatment, and a new clinically-approved test to diagnose prediabetes.
Each year 5% of the world’s population – more than 370 million people in 145 countries – receive a health diagnosis via a product manufactured by Randox.
For further information please contact the Randox PR team by emailing email@example.com or phoning 028 9442 2413.
Randox Laboratories is an international clinical diagnostic solutions company with over 35 years’ experience in the industry. Randox is a global market leader, providing revolutionary products for laboratories worldwide and is dedicated to improving health.
Randox Biosciences is part of Randox Laboratories and is dedicated to advancing scientific discovery, drug development and diagnostics. Spanning four key divisions; Life Sciences, Pharma Sciences, Research and Molecular; Randox Biosciences offers complete tailored solutions for clinical and research use.
From initial cultivation of raw materials for assay development, through to providing companion diagnostics, custom and molecular based assays across a range of therapy areas; Randox Biosciences is a trusted partner supplying quality diagnostic solutions to the clinical, life science, pharmaceutical, research and biopharma industries. We specialise in supplying academic centres, genetics laboratories and the global biopharmaceutical industry with products tailored to their specific needs.
Randox Biosciences Research team encompasses a knowledgeable group of who are dedicated to assisting your research project to completion. Recently, the research team has expanded to include Business Development Executives in America to support academic centres of excellence achieve their potential while utilising our quality products. We are proud to welcome Rebecca Newburg who will be focusing her efforts on the US-Midwest market and Celestine Eshiet who will be working on the US -West Coast.
We cover five areas of research such as Sport and Exercise, Cardiovascular, Metabolic, Immunology and Oncology. These five areas include our Metabolic Syndrome Array 1 & 2, Cytokine Arrays and Cardiac Array including CK-MB, H-FABP, Myoglobin and Troponin.
If you work in an academic centre and are interested in our variety of arrays, analysers whether that be chemistry or immunoassay analysers, or our reagents or quality control please do not hesitate to contact us at firstname.lastname@example.org.